6 results
With this study we aim to prove that personalized B cell tailored ocrelizumab treatment is non-inferior in the suppression of MS disease activity (clinically and radiologically) compared to the standard (fixed 24 week interval) treatment.
This Extension study will evaluate the effectiveness and safety of ocrelizumab in MS patients who were previously enrolled in a Roche sponsored ocrelizumab phase IIIb/IV parent trial.
The objective of this prospective, randomized study is to investigate the efficacy and safety of HSCT compared to the comparator group (alemtuzumab, cladribine or ocrelizumab) in patients with aggressive relapsing remitting MS. In Norway, the…
This study aims to investigate if fluorescence guided surgery performed with SGM-101 can improve R0 resection rates and allows to find additional malignant tissue in locally advanced and recurrent rectal cancer, or to achieve a *positive* change in…
Main objective:English To evaluate the longer-term safety of ocrelizumab in participants diagnosed with MS who were previously enrolled in Roche-sponsored\ Phase III pivotal studiesSecondary objectives:English To evaluate the longer-term efficacy of…
This study will evaluate the effectiveness and safety of ocrelizumab in PMS patients.